Malaria remains a serious problem in global public health, particularly widespread in South
America and in tropical regions of Africa and Asia. Chemotherapy is actually the only way to …

Increasing resistance of malaria parasites, P. falciparum in particular, towards existing
antimalarial drugs demands a serious search for novel targets for the development of new …

Malaria is currently endemic in 106 countries, with an estimated 216 million clinical cases
and nearly 655000 deaths in 2010 [1]. Five species of a parasite of Plasmodium genus are …

Abstract Falcipain-2 (FP-2) is a key cysteine protease from the malaria parasite Plasmodium
falciparum. Many previous studies have identified FP-2 inhibitors; however, none has yet …

Falcipain-2 is a papain family cysteine protease and an emerging antimalarial drug target. A
pseudo-tripeptide scaffold I was designed using in silico screening tools and the three …

We describe the design, combinatorial library synthesis and biological evaluation of
compounds with benzothiazole and triazole cores as inhibitors of falcipain, cysteine …

This paper describes the synthesis of a new class of peptidomimetic cysteine protease
inhibitors based on a 1, 4-benzodiazepine scaffold and on an electrophilic vinyl sulfone …

Malaria, particularly that one caused by Plasmodium falciparum, remains a serious health
problem in Africa, South America, and many parts of Asia where it afflicts about 500 million …

The Plasmodium falciparum cysteine protease falcipain is required for the degradation of
hemoglobin by erythrocytic malaria parasites. In prior studies, peptidyl inhibitors of falcipain …

Falcipain-2 (FP-2), a papain family cysteine protease of Plasmodium falciparum, is a
promising target for antimalarial chemotherapy. Designing inhibitors that are highly selective …